Qureight, known for its enterprise-grade imaging solutions for clinical trials, has successfully secured $20 million in Series B financing. The round was led by Molten Ventures and saw participation from existing investors including Hargreave Hale AIM VCT and Guinness Ventures. As the company develops its AI imaging capabilities, this funding aims to bolster its expanding influence in imaging for lung and heart diseases.
Throughout its journey, Qureight has consistently focused on enhancing clinical trial efficiency with advanced imaging tools. Notably, the company’s previous funding efforts emphasized building a comprehensive imaging platform. With continued investor confidence, Qureight is set on a new phase of growth that aligns with its strategic vision. In its last funding round, Qureight had emphasized building the foundational AI imaging laboratory, which now receives further expansion through this recent financing.
What Innovations Are Planned?
The fresh capital will empower Qureight to further enhance its AI imaging laboratory. The upcoming projects include deploying its 3D chest imaging Foundation Model, which aims to reduce both data need and time for disease model development. This model is expected to break new ground by addressing unmet needs in disease areas like asthma and pulmonary hypertension and optimizing trial designs.
How Will New Developments Impact the Market?
With the introduction of these new imaging models, Qureight plans to widen its scope beyond lung fibrosis. This expansion intends to capture new markets and establish Qureight as a leader among imaging CROs, utilizing a clinical trials platform designed to be both disease-agnostic and regulatory-compliant. Qureight’s innovations in imaging technology are anticipated to play a pivotal role in supporting biopharma partners by providing real-time insights and efficiency in clinical trials concerning fibrotic lung diseases.
CEO Dr. Muhunthan Thillai expressed enthusiasm for the ongoing journey.
“We are excited to bring on Molten Ventures to lead this new financing round and for Dr Inga Deakin to join our Board of Directors,” he stated. “Their ongoing support reflects the confidence in both our enterprise-grade imaging platform, and our world-class team.”
Thillai also highlighted the addition of new team members and emphasized the future expansion opportunities in markets with growing demand for advanced imaging.
Dr. Inga Deakin from Molten Ventures noted the innovation-driving potential of Qureight’s AI tools, highlighting its role in speeding up discovery in clinical research.
“Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research,” commented Deakin.
Qureight’s trajectory reveals a clear intent to enhance its industry standing through strategic funding and technology innovations. As the company expands its product offerings into areas with high demand, the focus remains on improving clinical trial designs and outcomes. The integration and advancements in 3D imaging models are expected to significantly streamline the processes for developing disease-specific models beyond just lung fibrosis.
The strategic funding and business plans of Qureight come at a time when the emphasis on innovation in clinical trials is more pressing than ever. The deployment of AI-driven imaging models caters to the need for higher precision, offering faster outcomes for trial endpoints, and meeting the broader demands of evolving healthcare systems. By combining robust funding strategies with cutting-edge imaging technology, Qureight is set to make notable strides in clinical trial efficacy.
